百济神州此前公布2024年第三季度财务业绩及研发管线进展。该公司的血液学后期管线的关键研究项目正在快速推进，同时肿瘤产品管线也在进一步扩大。数据显示，三季度百济神州有4个新分子实体（NME）进入临床开发阶段（2024年至今共有8个），且全年有望实现超过10个NME进入临床的目标。BEIGENE (06160) is up over 5%, as of the time of reporting, up 5.16%, priced at 110 HKD, with a transaction volume of 0.147 billion HKD.
According to Zhitong Finance APP, BEIGENE (06160) is up over 5%, as of the time of reporting, up 5.16%, priced at 110 HKD, with a transaction volume of 0.147 billion HKD.
On the news front, BEIGENE previously announced that the USA Food and Drug Administration (FDA) has approved Baizean (Tislelizumab) in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer expressing PD-L1 (≥1). This new indication is based on the results of a Global Phase 3 trial, demonstrating that Baizean combined with chemotherapy can significantly improve overall survival in patients with advanced gastric cancer. It is reported that this is the second approval granted to Baizean by the FDA in 2024.
BEIGENE previously announced its financial performance for the third quarter of 2024 and the progress of its R&D pipeline. The company's late-stage hematology pipeline's key research projects are progressing rapidly, while the oncology product pipeline is further expanding. Data shows that in the third quarter, BEIGENE had 4 new molecular entities (NME) entering clinical development (8 in total so far in 2024), with a target of over 10 NMEs entering clinical trials for the entire year.
